Vical Phase 3 Trial of Allovectin(R) Fails to Meet Efficacy Endpoints

Vical Phase 3 Trial of Allovectin(R) Fails to Meet Efficacy Endpoints

      Company Focusing Resources on Infectious Disease Vaccine Programs

              Conference Call and Webcast Today at 8:00 a.m. ET

SAN DIEGO, Aug. 12, 2013 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL)
today announced top-line results from a Phase 3 trial of Allovectin^®
(velimogene aliplasmid), an investigational intratumoral cancer immunotherapy,
in patients with metastatic melanoma. The 390-subject trial failed to
demonstrate a statistically significant improvement vs. first-line
chemotherapy for either the primary endpoint of objective response rate at 24
weeks or more after randomization or the secondary endpoint of overall
survival. Trial data will be further analyzed and detailed results will be
submitted for publication.

"We are disappointed that the trial did not meet either the primary or
secondary efficacy endpoints, even though we believe it was well-designed and
well-executed," said Vijay B. Samant, President and Chief Executive Officer of
Vical. "Based on this outcome, we are terminating the Allovectin^® program and
focusing our resources on our infectious disease vaccine programs." Mr. Samant
added, "We would like to recognize all of the patients and their families,
trial investigators and employees who participated in the conduct of this
trial and thank them for their efforts."

Continuing Programs

"In the coming weeks, we will make the necessary changes to focus resources on
our infectious disease vaccine programs and reduce expenses to conserve cash,"
said Mr. Samant. The company reported cash and investments of $70 million at
June 30, 2013, which it believes is adequate for its anticipated needs at
least through the end of 2014. Vical has multiple independent and
collaborative infectious disease vaccine programs:

  *Astellas Pharma Inc. initiated a multinational 500-patient Phase 3 trial
    of ASP0113, Vical's investigational therapeutic vaccine designed to
    control cytomegalovirus (CMV) in transplant recipients, for hematopoietic
    cell transplant (HCT) recipients in June and expects to initiate a Phase 2
    trial of ASP0113 for solid organ transplant (SOT) recipients later this
    year.
  *The company is planning to initiate a Phase 1/2 clinical trial of its
    Vaxfectin^®-formulated therapeutic vaccine against herpes simplex virus
    type 2 (HSV-2) before the end of 2013.
  *The company's Vaxfectin^®-formulated CyMVectin™ prophylactic vaccine,
    designed to prevent CMV infection before and during pregnancy, has
    completed preclinical development and has an allowed investigational new
    drug application (IND). Vical is seeking a partner for further
    development.
  *Vical has licensed its proprietary Vaxfectin^® adjuvant to Bristol-Myers
    Squibb Company for use in the production of antibodies, and to Cyvax,
    Inc., a privately held vaccine development company, for use in malaria
    vaccines. The company is pursuing additional licensing opportunities for
    Vaxfectin^®.
  *Two of the company's licensees have products approved for use in animal
    health applications:

    *In 2005, Vical's licensee Aqua Health, a subsidiary of Novartis Animal
      Health, received Canadian approval to market its proprietary product,
      Apex^®-IHN, a DNA vaccine to protect farm-raised salmon against
      infectious hematopoietic necrosis virus (IHNV).
    *In 2009, Vical's licensee Merial, now a subsidiary of Sanofi, received
      approval from the U.S. Department of Agriculture to sell a therapeutic
      DNA vaccine, ONCEPT^®, designed to aid in extending the survival time of
      dogs with oral melanoma.

Conference Call

Vical will conduct a conference call and webcast today, August 12, at 8:00
a.m. Eastern Time, to discuss the trial results and the company's path forward
with invited participants. The call and webcast are open on a listen-only
basis to any interested parties. To listen to the conference call, dial in
approximately ten minutes before the scheduled call to (913) 312-0657
(preferred) or (888) 233-8128 (toll-free) and reference confirmation code
7850968. A replay of the call will be available for 48 hours beginning about
two hours after the call. To listen to the replay, dial (719) 457-0820
(preferred) or (888) 203-1112 (toll-free) and enter replay passcode 7850968.
The call also will be available live and archived through the events page at
www.vical.com. For further information, contact Vical's Investor Relations
department by phone at (858) 646-1127 or by e-mail at ir@vical.com.

About Vical

Vical researches and develops biopharmaceutical products based on its patented
DNA delivery technologies for the prevention and treatment of serious or
life-threatening diseases. Potential applications of the company's DNA
delivery technology include DNA vaccines for infectious diseases or cancer, in
which the expressed protein is an immunogen; cancer immunotherapeutics, in
which the expressed protein is an immune system stimulant; and cardiovascular
therapies, in which the expressed protein is an angiogenic growth factor. The
company is developing certain infectious disease vaccines internally. In
addition, the company collaborates with major pharmaceutical companies and
biotechnology companies that give it access to complementary technologies or
greater resources. These strategic partnerships provide the company with
mutually beneficial opportunities to expand its product pipeline and address
significant unmet medical needs. Additional information on Vical is available
at www.vical.com.

Forward-Looking Statements

This press release contains forward-looking statements subject to risks and
uncertainties that could cause actual results to differ materially from those
projected. Forward-looking statements include net cash use guidance, as well
as anticipated developments in independent and collaborative programs,
including the initiation and completion of clinical trials. Risks and
uncertainties include whether Vical will effectively focus resources on its
infectious disease vaccine programs; whether Vical, Astellas or others will
continue development of ASP0113, the HSV-2 vaccine, CyMVectin™, or any other
independent or collaborative programs; whether Astellas will initiate the
planned Phase 2 trial of ASP0113 for SOT recipients later this year, if at
all; whether Vical or others will initiate a Phase 1/2 clinical trial of the
HSV-2 vaccine in the second half of 2013, if at all; whether Vical will
identify and obtain any additional product development opportunities; whether
any product candidates will be shown to be safe and efficacious in clinical
trials; the timing of clinical trials; whether Vical or its collaborative
partners will seek or gain approval to market any product candidates; and
additional risks set forth in the company's filings with the Securities and
Exchange Commission. These forward-looking statements represent the company's
judgment as of the date of this release. The company disclaims, however, any
intent or obligation to update these forward-looking statements.

CONTACT: Investors
         Vical Incorporated
         Alan R. Engbring
         +1-858-646-1127
         ir@vical.com
         www.vical.com
        
         Media
         W2O Group
         Susan Neath
         +1-212-301-7182
         sneath@w2ogroup.com

Vical Logo
 
Press spacebar to pause and continue. Press esc to stop.